摘要
目的研究2型血管紧张素Ⅱ受体(AT2R)激动剂化合物21(C21)对晚期糖基化终产物(AGE)刺激的NRK-52E大鼠近端肾小管上皮细胞分泌的细胞因子的影响及潜在机制。方法培养NRK-52E细胞,分为正常对照组和(25、50、100、200)mg/L AGE-牛血清白蛋白(BSA)刺激组。培养48 h后收集细胞,采用实时定量PCR检测NRK-52E细胞白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)mRNA的表达。间接ELISA检测细胞培养上清液中的IL-6、TNF-α蛋白水平。然后先用25 mg/L AGE-BSA刺激NRK-52E细胞48 h后分别给予(0.01、0.05、0.1)mmol/L C21分别处理24 h,采用实时定量PCR检测细胞蛋白激酶C(PKC)、核因子κB p65(NF-κB p65)及转化生长因子β1(TGF-β1)mRNA的表达,Western blot法检测细胞中PKC、NF-κB p65、TGF-β1蛋白表达。结果不同剂量的AGE-BSA刺激NRK-52E细胞均可明显增加IL-6、TNF-α的mRNA表达,而以25 mg/L AGE-BSA刺激NRK-52E细胞时,其IL-6、TNF-α的蛋白分泌增加更明显。以25 mg/L AGE-BSA刺激NRK-52E细胞48 h后,(0.01、0.05、0.1)mmol/L C21分别处理24 h,均可显著抑制AGE-BSA所诱导的NRK-52E细胞PKC、NF-κB p65及TGF-β1 mRNA和蛋白的表达。结论AGE-BSA促进NRK-52E细胞IL-6、TNF-α、PKC、NF-κB p65及TGF-β1表达,C21则抑制其作用。
Objective To investigate the effect and mechanism of compound 21(C21),an agonist of angiotensin II-2 receptor(AT2R)on the cytokine levels of NRK-52E cells stimulated by advanced glycation end products bovine serum albumin(AGE-BSA).Methods NRK-52E cells were divided into control and(25,50,100,200)mg/L AGE-BSA groups and cultured for 48 hours.The mRNA and protein expression levels of leukin-6(IL-6)and tumor necrosis factorα(TNF-α)were detected by real-time quantitative PCR and ELISA.The NRK-52E cells stimulated by AGE-BSA(25 mg/L)for 48 hours were then treated with(0.01,0.05,0.1)mmol/L C21 for 24 hours.The mRNA and protein expression levels of protein kinase C(PKC),nuclear factor kB p65(NF-kB p65)and transforming growth factorβ1(TGF-β1)were detected by qRT-PCR and Western blot analysis.Results The mRNA expression levels of IL-6 and TNF-αsignificantly increased in NRK-52E cells stimulated by AGE-BSA at diferent doses,with the greatest increase in the 25 mg/L AGE-BSA group.The mRNA and protein expression levels of PKC,NF-kB p65 and TGF-β1 in AGE-BSA-induced NRK-52E cells significantly decreased by(0.01,0.05,0.1)mmol/L C21.Conclusion AGE-BSA promotes the expression of IL-6,TNF-α,PKC,NF-kB p65 and TGF-β1 in NRK-52E cells,while C21 inhibits the effect of AGE-BSA on NRK-52E cells.
作者
黎懿慧
左丽
查艳
吴欣
刘畅
邓文丽
董蓉
达静静
LI Yihui;ZUO Li;ZHA Yan;WU Xin;LIU Chang;DENC Wenli;DONG Rong;DA Jingjing(Department of Nephrology,Guiyang First People's Hospital,Guiyang 550002;Department of Immunization,Guizhou Medical University,Guiyang 550004;Department of Nephrology,Guizhou Provincial People's Hospital,Guiyang 550002,China)
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2023年第3期230-235,共6页
Chinese Journal of Cellular and Molecular Immunology
基金
贵阳市卫生和计划生育委员会科学技术计划项目([2019]筑卫计科技合同字第005号)。